Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients
- El Chaer, F. (Speaker)
- Additional Authors and Affiliations (Speaker)
Activity: Talk or presentation › Oral presentation